Allergic reactions including very rare anaphylaxis and anaphylactic shock have been reported following palivizumab administration. In some cases, fatalities have been reported (see Post-marketing Experience under ADVERSE REACTIONS).
Medications for the treatment of severe hypersensitivity reactions, including anaphylaxis and anaphylactic shock, should be available for immediate use following administration of palivizumab. If a severe hypersensitivity reaction occurs, therapy with palivizumab should be discontinued. As with other agents administered to this population, if milder hypersensitivity reactions occur, caution should be used on re-administration of palivizumab.
As with any intramuscular injection, palivizumab should be given with caution to patients with thrombocytopenia or any coagulation disorder.
The single-use vial of palivizumab does not contain a preservative.
A moderate to severe acute infection or febrile illness may warrant delaying the use of palivizumab, unless, in the opinion of the physician, withholding palivizumab entails a greater risk. A mild febrile illness, such as a mild upper respiratory infection, is not usually reason to defer administration of palivizumab.